October 2019


In this Issue

Interventional Oncology

Practical Tips and Insights On The Future of Image-Guided Cancer Therapies.



Guest Chief Medical Editors’ Page

Enhancing Interventional Oncology

By Ripal T. Gandhi, MD, FSIR, FSVM; and David M. Liu, MD, FRCPC, FSIR


What’s New in Y-90?

Technical and procedural innovations in Y-90 radioembolization including existing and investigational next-generation technologies.

By Robert Abraham, MD, FRCPC, FSIR; Robert Lewandowski, MD, FSIR; Ripal T. Gandhi, MD, FSIR, FSVM; and David M. Liu, MD, FRCPC, FSIR

Year in Review: Top Papers in Interventional Oncology

Eric Wehrenberg-Klee, MD, and Suvranu “Shoey” Ganguli, MD, FSIR, provide an overview of the most significant interventional oncology articles published in the recent literature, with summaries on the impact that each has had on the field.

By Eric Wehrenberg-Klee, MD; and Suvranu “Shoey” Ganguli, MD, FSIR

Contemporary Management of Pancreatic Cancer

An update on state-of-the-art minimally invasive therapies, including recent advances in surgery, radiation therapy, ablative options, and endovascular therapies.

By Ripal T. Gandhi, MD, FSIR, FSVM; Horacio Asbun, MD; Michael Chuong, MD; Filipe Kunzler, MD; and Govindarajan Narayanan, MD

Top Tips in Interventional Oncology

Clinical and technical insights into treating hepatocellular carcinoma, cholangiocarcinoma, renal cell carcinoma, lung cancer, bone cancer, and in the palliative care setting.

By Siddharth A. Padia, MD; Theodore Bryan, MD; Rebecca Bennett, MD; Nadine Abi-Jaoudeh, MD, FSIR, CCRP; Raul N. Uppot, MD; Robert Suh, MD; Paul I. Mallinson, MBChB, FRCR, FRCPC; Peter L. Munk, MDCM, FRCPC, FSIR, FFRRCSI (Hon); Miyuki Sone, MD; and Yasuaki Arai, MD, FSIR, FCIRSE

Transradial Access for Hepatic Oncologic Interventions

Considerations for choosing the right access equipment.

By Darren Klass, MBChB, MD, MRCS, FCRC, FRCPC; Anastasia Hadjivassiliou, MBBS, FRCR, FRCPC; and John Chung, MD, FRCPC

Outpatient Interventional Oncology: Primum Non Nocere

Top tips for treating patients and avoiding complications in the outpatient setting.

By Edgar D. St. Amour, MD; David Hays, MD; and Ripal T. Gandhi, MD, FSIR, FSVM

Immunotherapy and Checkpoint Inhibitors: A Primer for the Interventional Radiologist

The basics of immunology, immunotherapy, and checkpoint inhibitors.

By Joseph P. Erinjeri, MD, PhD; and Daniel T. Sze, MD, PhD

Update on Treatment of Cancer-Associated Thrombosis

Current recommendations, results of recently completed trials on anticoagulation therapy, and applications of endovascular interventions.

By Nicholas Fidelman, MD


Mentors and Protégés: Conversations on Career and Craft With Robert J. Lewandowski, MD, FSIR

Adam Sucher, DO, talks with Dr. Lewandowski about his work in early interventional oncology and IVC filters, how to meld clinical and research interests, balancing competing priorities, and more.


Sponsored by Inari Medical

Is It Time to End the Therapeutic Nihilism Toward Treating VTE in Cancer Patients?

Cases highlighting the potential for early benefit and improved quality of life and function associated with the use of FlowTriever and ClotTriever Systems in patients with cancer and VTE.

With Sirish A. Kishore, MD; and William C. Dillon, MD, FACC


Sponsored by Medtronic

Intraprocedural Monitoring of Blood Flow Using FlowMet-R

By Mahmood K. Razavi, MD, FSIR, FSVM


An Interview With Akhilesh K. Sista, MD, FSIR, FAHA

Dr. Sista discusses the PE-TRACT trial’s origin, goals, and current status, as well as what it’s like to run a PERT in New York City.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.